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Edited by Sandro SonninoAbstract Flotillin-1 and arginase are both up-regulated in red
blood cell membrane of type 2 diabetic patients. For studying
why the soluble arginase can bind to the membrane and whether
such binding would modify arginase activity, the arginase1 and
related proteins were cloned and expressed. The results showed
that ﬂotillin-1 can interact with arginase1, and hence arginase
activity was up-regulated by 26.8%. It was estimated that about
61% of arginase1 is bound to the membrane mediated by ﬂotillin-
1. The arginase activity in diabetic patients was signiﬁcantly
higher than that of the controls (752.4 ± 38.5 U/mg protein vs
486.7 ± 28.7 U/mg protein).
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Current therapeutic approaches of type 2 diabetes were lar-
gely developed in the absence of deﬁned molecular target or
even solid understanding of disease pathogenesis [1,2]. The
blood should be regarded as the primary target tissue in diabe-
tes mellitus. It is reasonable to presume that the properties of
red blood cell (RBC) membrane must suﬀer variation during
disease development [3]. Our previous studies have provided
evidence that ﬂotillin-1 and arginase1 proteins were both up-
regulated in RBC membranes of type 2 diabetic patients [4].
Flotillins consist of two family members: ﬂotillin-1 (reggie-2)
and ﬂotillin-2 (reggie-1) [5]. Flotillin-1, ﬂotillin-2 and stomatin
are the most abundant membrane proteins in RBC lipid rafts.
They present as independently organized high-order oligomers
and act as separate scaﬀolding components at the cytoplasmic
face of RBC lipid rafts [6], which have been implicated in
numerous cellular processes including signal transduction
and membrane traﬃcking. Flotillin-1 plays an important role
in the second signaling pathway required for insulin-stimulated
glucose transport [7].
Arginase, the ﬁnal enzyme in the urea cycle, is responsible
for the hydrolysis of L-arginine to urea and L-ornithine. Argi-
nase has two forms, designated arginase1 and arginase2, and
arginase1 is present in the high concentration in RBC. Argi-
nase shares a common substrate, L-arginine, with nitric oxide
synthase (NOS), thus increased expression of arginase in dia-
betic human cavernosal tissue may down-regulate NO produc-
tion by competition with NOS [8]. It has been known that*Corresponding author. Fax: +86 21 65650149.
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doi:10.1016/j.febslet.2006.11.003NOS is involved in insulin action [9]. NOS was also found in
the human RBC [10,11]. The expression of arginase1 in RBC
membranes is also high in patients, which conﬁrmed that
NO and arginase pathways are involved in the development
of human type 2 diabetes [4]. Arginase activity is elevated in
livers of diabetic animals [12]. But up to now there is no infor-
mation available about why the soluble arginase is located on
cell membrane and how its enzymatic activity is regulated in
RBC. In present study, the cytoplasmic domain of band 3
(cdb3), arginase, ﬂotillin-1, and related proteins were cloned
and expressed in Escherichia coli for searching the partner in
association with arginase, and for studying the eﬀect of such
protein–protein interaction on the arginase activity.2. Materials and methods
2.1. Cloning, expressing and purifying GST-arginase1, His6-arginase1,
His6-cdb3, His6-ﬂotillin-1 and His6-ﬂotillin-2
For recombinant arginase1 with glutathione S-transferase (GST) or
hexahistidine (His6) tag, we used human embryo liver cDNA as nested
PCR reaction’s template, which was kindly provided by Dr. Ping Xu,
Laboratory of Genomic Physiology, School of Life Sciences, Fudan
University. The ﬁrst round primers were 5 0-TGAGGGTTGACT-
GACTGG-3 0 and 5 0-CAAGAGGGAATTTGTAGAG-3 0. The second
round primers used were 5 0-ATGAATTCATGAGCGCCAAGTCC-
3 0 and 5 0-AAACTCGAGTTACTTAGGTGGGTT-3 0 (the underlined
base pairs represent the sequences digested by restriction endonucle-
ases EcoR I and Xh0 I respectively). The product of second round
PCR reaction was double digested by EcoR I and Xho I, ligated with
EcoR I and Xho I double digested pGEX-4T-1. The positive clone was
veriﬁed by DNA sequencing. The His6-arginase1 was constructed by
double digested arginase1 fragment ligated with double digested
pT7470 containing both N-terminal and C-terminal His6 tag, which
was constructed from plasmid pET21a in our laboratory. GST-argi-
nase1 and His6-arginase1 were expressed and puriﬁed as Pharmacia’s
GST and His tag fusion protein protocols, respectively.
The recombinant fusion protein His6-cdb3, His6-ﬂotillin-1 and His6-
ﬂotillin-2 with hexahistidine tag in the C-terminal were constructed
and puriﬁed as described previously [13,14].
2.2. Preparation of membrane and cytoplasm fractions of RBC
Freshly drawn blood samples from 6 patients with Chinese type
2 diabetes were obtained from the Shanghai Changhai Hospital.
Subjects were 42–61 years old with a fasting glucose level of
(10.8 ± 1.8) mM and 5 fresh blood samples from healthy individuals
were obtained from the Shanghai Red-Cross Blood Center. RBC mem-
branes were prepared by hyposmotic lysis of RBC in 5 mM sodium
phosphate (pH 7.4). After hemolysis the membrane and cytoplasm
fractions were separated by centrifugation. Protein concentration
was calibrated using BCA protein assay reagent kit (Pierce Biotechnol-
ogy, Rockford, IL, USA).
2.3. Far-Western blot
The recombinant proteins were electrophoresed on SDS–PAGE,
and then transferred onto nitrocellulose membrane. The nitrocelluloseblished by Elsevier B.V. All rights reserved.
Fig. 1. SDS–PAGE analysis of the expression and puriﬁcation of
recombinant arginase1 protein with His6 or GST tag. (+), induced
bacterial lysate; (+)S, soluble fraction extracted by PBS (5 mM sodium
phosphate, pH 7.4); FT, ﬂow through; E, elution with imidazole
(200 mM) for His6-arginase1 or glutathione (10 mM) for GST-
arginase1.
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pH 7.4, 0.05% (v/v) Tween 20, and 5% (w/v) low fat milk powder) over-
night at 4 C. The nitrocellulose was then incubated with 100 lg of a
probe protein added to the binding buﬀer (150 mM NaCl, 50 mM
Tris–HCl, pH 7.0, and 1% (w/v) low fat milk powder) for 4 h at room
temperature. After washing, the membrane was incubated with anti-
band 3 (Sigma Inc., St. Louis, MO, USA) or anti-ﬂotillin monoclonal
antibody (BD Biosciences, San Jose, CA, USA) and secondary anti-
body together for 1 h at 37 C. Finally, membrane-bound antibodies
were detected using SuperSignal WestPico (Pierce Biotechnology,
Rockford, IL, USA) chemiluminescent substrate solution for 1 min
and then pressed against an autoradiographic ﬁlm.
2.4. Pull-down assay
The puriﬁed recombinant GST-arginase1 or control GST protein
was loaded on the MagneGST glutathione particles (20 ll) equilibrated
with buﬀer A (PBS containing 0.1% (v/v) Triton X-100) and blocked
by bovine serum albumin (100 lg). One hundred microgram of the
probe protein (His6-cdb3, His6-ﬂotillin-1 or His6-ﬂotillin-2) was loaded
on the particles. The mixture was shaken gently for 5 h at 4 C. After
washing with PBS containing 0.1% (v/v) Triton X-100, the proteins
were analyzed by SDS–PAGE followed with Western blot as described
previously [13].
2.5. Assay of arginase1 activity
The arginase activity of recombinant His6-arginase1 or arginase in
RBC was determined with standard procedures for the detection of
urea by reaction with diacetyl monoxime [15]. Brieﬂy, 50 ll of samples
was added to a reaction buﬀer (0.1 mM Tris–HCl buﬀer, pH 7.4) con-
taining 0.2 M L-arginine and 0.5 lMMnCl2, and incubated for 60 min
at 37 C followed by stopping reaction by addition of 1 M HCl. Then
the concentration of urea was measured. The arginase activity was cal-
culated and expressed in units per mg of proteins. One unit of arginase
activity is equivalent to the conversion of 1 lmol urea/h at 37 C.3. Results
3.1. Expression and puriﬁcation of GST-arginase1, His6-
arginase1, His6-cdb3, His6-ﬂotillin-1 and His6-ﬂotillin-2
The expression of soluble fraction of the recombinant pro-
tein ﬂotillin-1 or ﬂotillin-2 with GST tag or thioredoxin tag
in the N-terminal or His6 tag in C-terminal was quite low (data
not shown). So we choose His6 tag to express and purify the
recombinant proteins for the reason of reducing the eﬀect of
large fusion tag [14].
The solubility of the fusion protein arginase1 with GST or
His6 tag was both high. The fusion proteins of the desired
molecular weight, approximately 37-kDa for His6-arginase1
and 63-kDa for GST-arginase1, were expressed. GST-argi-
nase1 and His6-arginase1were puriﬁed by MagneGST glutathi-
one particles and Ni-NTA column, respectively (Fig. 1).
3.2. Interactions among ﬂotillin-1, ﬂotillin-2, cdb3 and arginase1
A series of Far-Western blot assay with recombinant pro-
teins His6-ﬂotillin-1, His6-ﬂotillin-2 and His6-cdb3 were per-
formed, respectively. There was interaction between ﬂotillin-1
and ﬂotillin-2 (Fig. 2A and B). Using pull-down assay the asso-
ciation of GST-arginase1 with His6-ﬂotillin-1 was identiﬁed
(Fig. 2C). We also tried to study the association of GST-argi-
nase1 with His6-ﬂotillin-1 by Far-Western assay, but signiﬁ-
cant interaction was not observed (data not shown). This
infers that the proper conformation of the proteins would be
necessary for interaction between arginase1 and ﬂotillin-1.
3.3. Modulation of arginase1 activity by ﬂotillin-1
What would be the physiological role of ﬂotillin-arginase
interaction in RBC? Fig. 3A shows that the enzymatic activityof His6-arginase1 increased signiﬁcantly after interaction with
His6-ﬂotillin-1, meanwhile cdb3 or ﬂotillin-2 has nomodulation
eﬀect on arginase activity. The modulation of arginase1 activity
by ﬂotillin-1 appears a dose dependence manner as shown in
Fig. 3B. The arginase1 activity can be up-regulated by 26.8%.
3.4. Diﬀerent arginase activity in cytoplasm and membrane of
RBC
Our previous work indicated that the protein spot of soluble
arginase always appeared in the two-dimensional gel of RBC
membranes [4]. So it would be interesting to compare the enzy-
matic activities in both membrane and cytoplasm circum-
stances for the purpose of identifying the location of
arginase in RBC. Table 1 shows the enzymatic levels of argi-
nase in cytoplasm and membrane of RBC, respectively. The
result infers that quite a lot of arginase would be bound on
the membrane of RBC.
3.5. Comparison of arginase activity between RBC membranes
from type 2 diabetic patients and healthy controls
The enzymatic levels of arginase from 6 diabetic patients
and 5 healthy subjects were measured. Arginase activity
(means ± S.D.) of RBC membrane from diabetic patients and
healthy controls is 752.4 ± 38.5 U/mg and 486.7 ± 22.6 U/mg,
respectively. That is, the arginase activity in RBC membrane
was increased by about 54.6% (P < 0.05, compared to healthy
controls, Student’s t-test) in diabetic patients.4. Discussion
Human ﬂotillin-1 is a speciﬁc hydrophobic protein of bio-
membrane microdomain lipid rafts, which exerts important
process in the pathway of insulin-stimulated translocation of
glucose transporter 4 in adipose and muscle cells [16,17]. Pre-
vious studies have proved that ﬂotillin-1 was up-regulated in
RBC membrane of type 2 diabetic patients [4]. But we still
Fig. 2. Association among ﬂotillin-1, ﬂotillin-2, cdb3 and arginase1.
Fusion proteins were run on SDS–PAGE and subjected to Far-
Western blot (A and B) or pull-down assay (C). (A) His6-F1 (positive
control), His6-F2 and His6-cdb3 (each 15 lg) were transferred onto
nitrocellulose membrane, and His6-F1 (100 lg) was added (lane 2 and
3) as a probe protein using anti-ﬂotillin-1 monoclonal antibody. (B)
His6-F2 (positive control), His6-F1 and His6-cdb3 (each 15 lg) were
transferred to nitrocellulose membrane, probe protein His6-F2 was
added (lane 5 and 6), detected by anti-ﬂotillin-2 monoclonal antibody.
(C) Puriﬁed GST (negative control) and GST-ARG were loaded on the
MagneGST glutathione particles balanced with buﬀer A (PBS
containing 0.1% (v/v) Triton X-100). The target proteins of puriﬁed
recombinant His6-cdb3, His6-F1 and His6-F2 were loaded on the resin
with gentle shaking 4 h at 4 C. After washing, the proteins eluted were
analyzed by SDS–PAGE followed by Western-blot using anti-band 3,
anti-ﬂotillin-1 and anti-ﬂotillin-2 monoclonal antibodies, respectively.
F1 and F2 represent ﬂotillin-1 and ﬂotillin-2, respectively. ARG
represents arginase.
Fig. 3. The eﬀect of interaction between arginase1 and ﬂotillin-1 on
arginase activity. (A) The excessive amount of His6-ﬂotillin-1,
His6-ﬂotillin-2 and His6-cdb3 was incubated with His6-arginase1 for
4 h at 37 C, respectively, followed by adding to reaction buﬀer for
60 min at 37 C. The urea concentration in each sample was then
measured. The arginase1 activity was (2.11 ± 0.31) · 105 U/mg (con-
trol), (2.68 ± 0.08) · 105 U/mg (ARG + F1), (2.16 ± 0.12) · 105 U/mg
(ARG + F2) and (2.20 ± 0.15) · 105 U/mg (ARG + cdb3). Data were
from six independent experiments (means ± S.D., *P < 0.05 compared
to control, Student’s t-test). (B) Dose dependence of the eﬀect of
ﬂotillin-1 on arginase 1 activity. His6-arginase1 (1 mg) was incubated
with diﬀerent amount of ﬂotillin-1 (0–6.0 mg) in 5 ml of PBS (pH 7.4)
for 4 h at 37 C, then 100 ll of each sample was added to the reaction
buﬀer for 60 min at 37 C. The urea concentration in each sample was
then measured. Data were from three independent experiments
(means ± S.D.). F1 and F2 represent His6-ﬂotillin-1 and His6-ﬂotil-
lin-2, respectively. ARG represents His6-arginase1.
Table 1
Arginase1 activities in the membranes and cytoplasm of RBCa
Blood samplesb
Membranes Cytoplasm
Arginase activity (U/mg protein) 486.7 ± 22.6 4.7 ± 1.3
aRBCs were hemolyzed in ﬁve volumes of 5 mM sodium phosphate
(pH 7.4), and the cytoplasm and membranes were separated by cen-
trifugation at 20,000 · g. The enzymatic activities of both membranes
and cytoplasm fractions were assayed. The arginase activities in the
membranes and cytoplasm were calculated according to the total
proteins in the membranes and cytoplasm, respectively. Protein con-
centration was calibrated using BCA protein assay kit.
bData were from ﬁve independent experiments (means ± S.D.).
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diabetes in molecular level. It has been reported that ﬂotillins 1
and 2 form a high-order oligomeric complex with stomatin in
RBC lipid rafts [6]. In accordance with this report, we did ﬁnd
the direct interaction between ﬂotillin-1 and ﬂotillin-2 (Fig. 2A
and B), moreover, our present study also identiﬁed the interac-
tion between ﬂotillin-1 and arginase1 (Fig. 2C). Out of our pre-
vious presumption [4], it was not found that there would be the
interaction of arginase1 with cdb3. Cdb3, acts as an attach-
ment site for RBC skeleton by binding ankyrin, protein 4.1
and protein 4.2, helping to maintain the mechanical properties
and integrity of the cell. It was well demonstrated that the abil-
ity of band 3 to anchor the membrane skeleton to the lipid bi-
layer is one of the essential factors to contribute to the
deformability and stability of the human RBC membrane
using ektacytometer and micropipette aspiration technique
[18]. Besides, cdb3 also interacts with several glycolytic en-
zymes, p72(syk) protein tyrosine kinase, hemoglobin andhemichromes to take part in regulating the metabolic activity
and sensing the aged or abnormal RBCs [19,20]. So it would
be natural to make a similar suggestion that the display of sol-
uble arginase in the two-dimensional gel of the membrane
6564 M. Jiang et al. / FEBS Letters 580 (2006) 6561–6564fraction would be due to its interaction with cdb3. But this is
not the case according to the present study. In addition, the di-
rect association of arginase1 with glucose transporter 1, an-
other major membrane protein in the RBC membrane, was
also not observed (data not shown). The interaction of soluble
enzyme arginase with ﬂotillin-1 would be ﬂotillin-1’s another
role. In other words, arginase pathways and glucose trans-
porter translocation would be linked together to involve in
the development of human type 2 diabetes.
Fig. 3A shows that the activity of the recombinant His6-argi-
nase1 was (2.11 ± 0.31) · 105 U/mg protein, which is much
higher than that of RBC membranes (486.7 ± 28.7 U/mg total
protein) (Table 1). This is obvious because the recombinant
His6-arginase1 was puriﬁed protein, meanwhile the arginase
activity of RBC membranes was calculated according to the
total proteins on the membranes. The reason is similar for big
diﬀerence of the arginase activity between membranes and cyto-
plasm fractions of RBC (Table 1) because of the diﬀerent ratio
of amount of arginase in membrane and cytoplasm. But the
interesting point is that the signiﬁcant arginase activity was
found in RBC membranes, which demonstrated again that sol-
uble arginase can bind to the RBCmembrane in vivo. The value
of membrane-bound fraction of the arginase1 can be roughly
estimated. For humanRBC, the average amount of hemoglobin
in a RBC is 25–35 pg, and the total amount of membrane pro-
teins of a RBC is 0.57 pg [21]. As a ﬁrst approximate, the enzy-
matic activity of arginase1 on the membrane is assumed to be
1.28-fold higher than in cytoplasm (Fig. 3). Based on these
parameters and the data of Table 1, it can be calculated that
about 61% of arginase1 in RBC is bound to the membrane.
To eliminate the tag eﬀect, the recombinant His6-arginase1
was used to determine the arginase activity (Fig. 3). But in fact
the enzymatic activity of GST-arginase1 was similar to that of
His6-arginase1, and this means that there was no signiﬁcant
functional diﬀerence between His6-arginase1 and GST-argi-
nase (data not shown).
Arginase is an enzyme that shares a common substrate with
NOS, thus arginase may down-regulate NO production by
competing with NOS for the substrate, L-arginine [8]. Alterant
arginase is implicated in the pathophysiology of many symp-
toms, including diabetic disease specially [8,12]. However, the
molecular mechanism that leads to the elevation of the argi-
nase activity in diabetes is still not known. The present studies,
for the ﬁrst time, show that the soluble arginase can locate on
the membrane in RBC through its association with membrane
protein ﬂotillin-1, and hence its enzymatic activity is up-regu-
lated. The result also indicates that this would be another way
to connect the membrane and the cytosol in RBC besides of
cdb3. This conclusion is further conﬁrmed by the experiment
of dose dependence of the eﬀect of ﬂotillin-1 on arginase 1
activity (Fig. 3B).
In conclusion, the present investigation shows that arginase
can bind to the membrane through its association with ﬂotil-
lin-1 but not via cdb3. Such interaction can up-regulate argi-
nase1 activity. The abnormality of arginase activity in RBC
membrane of diabetic patients may play an important role in
the development of human type 2 diabetes.Acknowledgement: The work was supported by the grants 30370380,
30500113 and 30670499 from the National Natural Science Founda-
tion of China and the grant 2001CB5102 from the National Basic Re-
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